Proteostasis restoration: a new metric for tau immunotherapy efficacy
Open Access
- 21 November 2024
- journal article
- editorial
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (1) , 9-11
Abstract
This scientific commentary refers to ‘Proteostasis as a fundamental principle of Tau immunotherapy’ by Cruz et al. (https://doi.org/10.1093/brain/awae254).Keywords
Funding Information
- Chaire de recherche sur les aphasies primaires progressives – Fondation de la Famille Lemaire
- FRSQ
- NSERC (RGPIN/05862- 2016)
- CIHR (IC121689)
- Alzheimer Society of Canada (19-04)
This publication has 7 references indexed in Scilit:
- Alzheimer's disease: From immunotherapy to immunopreventionCell, 2023
- The most valuable player or the tombstone: is tau the correct target to treat Alzheimer’s disease?Brain, 2023
- Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialThe Lancet Neurology, 2021
- From beta amyloid to altered proteostasis in Alzheimer’s diseaseAgeing Research Reviews, 2020
- A walk through tau therapeutic strategiesActa Neuropathologica Communications, 2019
- Caspase-2 cleavage of tau reversibly impairs memoryNature Medicine, 2016
- Classification and basic pathology of Alzheimer diseaseActa Neuropathologica, 2009